Partnerships and co-selling ROI benchmarks and payback periods for healthcare and life sciences
The real ROI, CAC payback, and time-to-value ranges for partnerships and co-selling across B2B categories. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install partnerships and co-selling has to reflect that reality from day one.
Payback is the honest ROI question for partnerships and co-selling: how many months from first dollar spent to first dollar returned. Below are the ranges we see, split by category and starting condition.
Best-case payback for partnerships and co-selling in a category with warm demand: 60–90 days. Median: 4–6 months. Cold category with no warm inbound: 6–9 months.
The dominant driver of payback is trigger quality, not spend. One great partner is worth ten marketing hires — teams that respect this get inside the shorter range.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Partnerships and co-selling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Sourced and influenced pipeline from partners is the leading indicator. If it moves inside the first six weeks, payback usually lands in the best case. If it stalls for a month, replan.
ROI compounds after payback. By month 12, well-run partnerships and co-selling functions typically produce 3–5x return on total cost of ownership.
Bad ROI has one signature: signing MOUs no one operationalises. Where you see broken payback, you see this pattern almost every time.
Benchmarks are useful as a sanity check, not a target. The target is the one your finance team commits to on the current-year plan; benchmarks tell you if that target is plausible.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing partnerships and co-selling properly rather than half-heartedly across three vendors.
Frequently asked questions
Partnerships · healthcare — answered
- Does partnerships and co-selling work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- What is a good payback period for partnerships and co-selling?
- Best case 60–90 days; median 4–6 months; cold-category 6–9 months.
- What drives partnerships and co-selling ROI more than anything else?
- Trigger quality. Spend and headcount matter less.
- When does partnerships and co-selling start to compound?
- Typically after month six, once the operating rhythm is muscle memory.
- What is the leading indicator of poor ROI?
- Sourced and influenced pipeline from partners stalling for four consecutive weeks.
- What is the healthcare specific pitfall with partnerships and co-selling?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under partnerships · healthcare